Severe immune-related adverse events of immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trials
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Immunology,Immunology and Allergy
Link
https://link.springer.com/content/pdf/10.1007/s00262-022-03140-5.pdf
Reference62 articles.
1. World Health Organization (2018) Cancer fact sheet. https://www.who.int/news-room/fact-sheets/detail/cancer
2. Goldstraw P, Chansky K, Crowley J (2016) The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 11(1):39–51
3. Torre L, Siegel R, Jemal A (2016) Lung cancer statistics. Adv Exp Med Biol 893:1–19
4. Molina J, Yang R, Cassivi P et al (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin 83:584–594
5. Bironzo P, Di M (2018) A review of guidelines for lung cancer. J Thorac Dis 10(Suppl. 13):S1556–S1663
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Treatment-related adverse events of immune checkpoint inhibitors in clinical trials: a systematic review and meta-analysis;Frontiers in Oncology;2024-05-17
2. Adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: a safety analysis of clinical trials and FDA pharmacovigilance system;Frontiers in Immunology;2024-04-30
3. Comparative safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and network meta-analysis;European Archives of Oto-Rhino-Laryngology;2024-02-15
4. Uncovering the flip side of immune checkpoint inhibitors: a comprehensive review of immune-related adverse events and predictive biomarkers;International Journal of Biological Sciences;2024
5. Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative study;Cancer Immunology, Immunotherapy;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3